Research Article
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Table 1
Summary of subject characteristics.
| | | SSc | SSc-PAH | SLE-PAH | SSc-ILD limited | SSc-ILD extensive | IPAH | Control |
| | Female sex (%) | 16 (100%) | 5 (71%) | 7 (100%) | 7 (88%) | 3 (75%) | 7 (78%) | 5 (50%) | | Age in years (median) | 51 | 51 | 37 | 54.5 | 56.5 | 41.0 | 33.5 | | Limited cutaneous subtype (%) | 15 (94%) | 5 (71%) | NA | 7 (88%) | 2 (50%) | NA | NA | | Manifestations (%) | | | | | | | | | Calcinosis | 6 (38%) | 2 (29%) | NA | 1 (13%) | 2 (50%) | NA | NA | | Raynaud’s phenomenon | 16 (100%) | 7 (100%) | NA | 8 (100%) | 4 (100%) | NA | NA | | Esophageal dysmotility | 13 (81%) | 6 (86%) | NA | 5 (63%) | 4 (100%) | NA | NA | | Sclerodactyly | 12 (75%) | 6 (86%) | NA | 5 (63%) | 4 (100%) | NA | NA | | Telangiectasia | 13 (81%) | 7 (100%) | NA | 5 (63%) | 3 (75%) | NA | NA | | Renal crisis | 0 | 0 | NA | 0 | 0 | NA | NA | | Abnormal nailfold capillaries | 5 (31%) | 5 (71%) | NA | 3 (38%) | 2 (50%) | NA | NA | | Digital ulcers | 3 (19%) | 5 (71%) | NA | 2 (25%) | 2 (50%) | NA | NA | | ScL-70 antibody | 1 (6%) | 0 | NA | 2 (25%) | 2 (50%) | NA | NA | | Anti-centromere antibody | 6 (38%) | 1 (14%) | NA | 2 (25%) | 1 (25%) | NA | NA | | Hemodynamics | | | | | | | | | mPAP mmHg (median, IQR) | NA | 40 (37–48) | 42 (39–48) | NA | 38 (34–40) | 44 (42–53) | NA | | LVEDP mmHg (median, IQR) | NA | 8 (4–10) | 6 (6–11) | NA | 6 (4–8) | 9 (7–13) | NA | | Comorbidities (%) | | | | | | | | | Asthma | 2 (13%) | 0 | 2 (29%) | 1 (13%) | 0 | 2 (22%) | 0 | | COPD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | OSA | 2 (13%) | 0 | 1 (14%) | 1 (13%) | 0 | 1 (11%) | 0 | | Systemic hypertension | 4 (25%) | 1 (14%) | 1 (14%) | 2 (25%) | 2 (50%) | 3 (33%) | 0 | | Atrial fibrillation | 0 | 0 | 0 | 0 | 1 (25%) | 0 | 0 | | CAD | 1 (6%) | 1 (14%) | 0 | 0 | 0 | 1 (11%) | 0 | | Smoking history (%) | | | | | | | | Current | 2 (13%) | 1 (14%) | 0 | 0 | 0 | 0 | NA | | Former | 6 (38%) | 3 (43%) | 2 (29%) | 2 (25%) | 2 (50%) | 3 (33%) | NA | | Medication (%) | | | | | | | | | NSAID | 2 (13%) | 2 (29%) | 2 (29%) | 5 (63%) | 0 | 2 (22%) | 0 | | Prednisone | 0 | 2 (29%) | 5 (71%) | 3 (38%) | 2 (50%) | 0 | 0 | | Inhaled corticosteroids | 1 (6%) | 0 | 0 | 1 (13%) | 0 | 1 (11%) | 0 | | Pulmonary function tests | | | | | | | | | FEV1% predicted (median) | 92.0 | 95.0 | 78.0 | 85.0 | 71.0 | 87.5 | NA | | FVC% predicted (median) | 97.0 | 95.0 | 81.0 | 89.0 | 65.0 | 90.5 | NA | | TLC% predicted (median) | 96 | 104 | 83 | 95 | 74 | 90 | NA | | DLCO% predicted (median) | 72.0 | 48.5 | 73.5 | 58.0 | 65.5 | 70.5 | NA |
|
|
mPAP: mean pulmonary artery pressure, LVEDP: left ventricular end-diastolic pressure, COPD: chronic obstructive pulmonary disease, OSA: obstructive sleep apnea, CAD: coronary artery disease, NSAID: nonsteroidal anti-inflammatories, FEV1: forced expiratory volume in one second, FVC: forced vital capacity, TLC: total lung capacity, DLCO: diffusing capacity.
|
